The discovery and validation of graft-versus-host disease (GvHD) biomarkers remains a vital area of hematopoietic stem-cell transplantation (HSCT) research. In this video, Kirk Schultz, MD, British Columbia Children's Hospital, Vancouver, Canada, highlights recent data regarding both acute and chronic GvHD biomarkers, including advances from the ABLE network and Mount Sinai Acute GvHD International Consortium (MAGIC) group. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

свернуть